EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE
LOE Approachingbrompheniramine maleate; pseudoephedrine hydrochloride
NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE (brompheniramine maleate; pseudoephedrine hydrochloride). Approved for nasal congestion due to the common cold, hay fever, other upper respiratory allergies temporarily relieves these symptoms due to hay fever (allergic rhinitis) runny nose itchy and 2 more indications. First approved in 1996.
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EFIDAC 24 is an oral extended-release combination tablet containing brompheniramine maleate (a first-generation antihistamine) and pseudoephedrine hydrochloride (a nasal decongestant). It treats nasal congestion, runny nose, sneezing, and itchy/watery eyes associated with the common cold, hay fever, and upper respiratory allergies by blocking histamine receptors and constricting nasal blood vessels to restore freer breathing.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling smaller brand teams and focus on defensive positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (5)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.